Skye Bioscience (SKYE) Change in Accured Expenses (2012 - 2026)

Skye Bioscience (SKYE) has reported Change in Accured Expenses for 15 consecutive years, with -$1.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 577.65% year-over-year to -$1.0 million; the TTM figure through Mar 2026 stood at $1.1 million (up 194.49% YoY), while the FY2025 annual figure was $2.3 million, up 922.12% from the prior year.
• Change in Accured Expenses eased to -$1.0 million in Q1 2026 per SKYE's latest filing, from $292427.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.3 million in Q3 2025 and bottomed at -$1.0 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $120201.7 across 5 years, with a median of $44087.0 in 2022.
• On a YoY basis, Change in Accured Expenses climbed as much as 791.69% in 2023 and fell as far as 1975.08% in 2023.
• Skye Bioscience's Change in Accured Expenses stood at $182461.0 in 2022, then surged by 339.06% to $801120.0 in 2023, then slumped by 210.29% to -$883569.0 in 2024, then soared by 133.1% to $292427.0 in 2025, then slumped by 453.96% to -$1.0 million in 2026.
• Business Quant data shows SKYE's Change in Accured Expenses at -$1.0 million in Q1 2026, $292427.0 in Q4 2025, and $2.3 million in Q3 2025.